FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783616522> ?p ?o ?g. }

• W2783616522 endingPage "881.e6" @default.
• W2783616522 startingPage "872" @default.
• W2783616522 abstract "BackgroundInterleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function.ObjectiveEvaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD).MethodsWe performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point.ResultsAt 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated patients than placebo-treated patients at 12 weeks (21.6 ± 3.8 vs 9.6 ± 4.2, P = .029) and 20 weeks (27.4 ± 3.9 vs 11.5 ± 5.1, P = .010). At 12 weeks, improvements in body surface area involvement in the entire population were significantly stronger in the drug-treated than placebo-treated patients (12.4% ± 2.4 vs 6.2% ± 2.7; P = .009), and in the severe AD subset, the decline in Investigator Global Assessment was significantly higher in the drug-treated than placebo-treated patients (0.7 ± 0.2 vs 0.3 ± 0.1; P = .034). All scores showed progressive improvements after last dosing (10 weeks) until end of study (20 weeks). Common adverse events were upper respiratory tract infections.LimitationsThe limited sample size and lack of assessment with Eczema Area and Severity Index and a pruritus numerical rating scale were limiting factors. Significance was primarily obtained in severe AD.ConclusionFezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing. Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function. Evaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD). We performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point. At 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated patients than placebo-treated patients at 12 weeks (21.6 ± 3.8 vs 9.6 ± 4.2, P = .029) and 20 weeks (27.4 ± 3.9 vs 11.5 ± 5.1, P = .010). At 12 weeks, improvements in body surface area involvement in the entire population were significantly stronger in the drug-treated than placebo-treated patients (12.4% ± 2.4 vs 6.2% ± 2.7; P = .009), and in the severe AD subset, the decline in Investigator Global Assessment was significantly higher in the drug-treated than placebo-treated patients (0.7 ± 0.2 vs 0.3 ± 0.1; P = .034). All scores showed progressive improvements after last dosing (10 weeks) until end of study (20 weeks). Common adverse events were upper respiratory tract infections. The limited sample size and lack of assessment with Eczema Area and Severity Index and a pruritus numerical rating scale were limiting factors. Significance was primarily obtained in severe AD. Fezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing." @default.
• W2783616522 created "2018-01-26" @default.
• W2783616522 creator A5001585273 @default.
• W2783616522 creator A5001886451 @default.
• W2783616522 creator A5012281844 @default.
• W2783616522 creator A5015778932 @default.
• W2783616522 creator A5024365532 @default.
• W2783616522 creator A5027937292 @default.
• W2783616522 creator A5035849206 @default.
• W2783616522 creator A5037241951 @default.
• W2783616522 creator A5038505651 @default.
• W2783616522 creator A5039389925 @default.
• W2783616522 creator A5041820710 @default.
• W2783616522 creator A5044627353 @default.
• W2783616522 creator A5053402932 @default.
• W2783616522 creator A5060844419 @default.
• W2783616522 creator A5061063698 @default.
• W2783616522 creator A5069569862 @default.
• W2783616522 creator A5080337749 @default.
• W2783616522 creator A5082303364 @default.
• W2783616522 creator A5087191636 @default.
• W2783616522 date "2018-05-01" @default.
• W2783616522 modified "2023-10-11" @default.
• W2783616522 title "Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial" @default.
• W2783616522 cites W1491934715 @default.
• W2783616522 cites W1532206496 @default.
• W2783616522 cites W1576903429 @default.
• W2783616522 cites W2003774999 @default.
• W2783616522 cites W2005897922 @default.
• W2783616522 cites W2009848789 @default.
• W2783616522 cites W2012868073 @default.
• W2783616522 cites W2115461663 @default.
• W2783616522 cites W2117159275 @default.
• W2783616522 cites W2118630839 @default.
• W2783616522 cites W2156992552 @default.
• W2783616522 cites W2174132185 @default.
• W2783616522 cites W2326570504 @default.
• W2783616522 cites W2408811191 @default.
• W2783616522 cites W2411361269 @default.
• W2783616522 cites W2496806206 @default.
• W2783616522 cites W2517755348 @default.
• W2783616522 cites W2524051065 @default.
• W2783616522 cites W2568118550 @default.
• W2783616522 cites W2593200577 @default.
• W2783616522 cites W2598094671 @default.
• W2783616522 cites W2604249065 @default.
• W2783616522 cites W2606268778 @default.
• W2783616522 cites W2624672837 @default.
• W2783616522 cites W2760088364 @default.
• W2783616522 cites W2790454153 @default.
• W2783616522 cites W4211145137 @default.
• W2783616522 doi "https://doi.org/10.1016/j.jaad.2018.01.016" @default.
• W2783616522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29353025" @default.
• W2783616522 hasPublicationYear "2018" @default.
• W2783616522 type Work @default.
• W2783616522 sameAs 2783616522 @default.
• W2783616522 citedByCount "227" @default.
• W2783616522 countsByYear W27836165222018 @default.
• W2783616522 countsByYear W27836165222019 @default.
• W2783616522 countsByYear W27836165222020 @default.
• W2783616522 countsByYear W27836165222021 @default.
• W2783616522 countsByYear W27836165222022 @default.
• W2783616522 countsByYear W27836165222023 @default.
• W2783616522 crossrefType "journal-article" @default.
• W2783616522 hasAuthorship W2783616522A5001585273 @default.
• W2783616522 hasAuthorship W2783616522A5001886451 @default.
• W2783616522 hasAuthorship W2783616522A5012281844 @default.
• W2783616522 hasAuthorship W2783616522A5015778932 @default.
• W2783616522 hasAuthorship W2783616522A5024365532 @default.
• W2783616522 hasAuthorship W2783616522A5027937292 @default.
• W2783616522 hasAuthorship W2783616522A5035849206 @default.
• W2783616522 hasAuthorship W2783616522A5037241951 @default.
• W2783616522 hasAuthorship W2783616522A5038505651 @default.
• W2783616522 hasAuthorship W2783616522A5039389925 @default.
• W2783616522 hasAuthorship W2783616522A5041820710 @default.
• W2783616522 hasAuthorship W2783616522A5044627353 @default.
• W2783616522 hasAuthorship W2783616522A5053402932 @default.
• W2783616522 hasAuthorship W2783616522A5060844419 @default.
• W2783616522 hasAuthorship W2783616522A5061063698 @default.
• W2783616522 hasAuthorship W2783616522A5069569862 @default.
• W2783616522 hasAuthorship W2783616522A5080337749 @default.
• W2783616522 hasAuthorship W2783616522A5082303364 @default.
• W2783616522 hasAuthorship W2783616522A5087191636 @default.
• W2783616522 hasBestOaLocation W27836165221 @default.
• W2783616522 hasConcept C126322002 @default.
• W2783616522 hasConcept C142724271 @default.
• W2783616522 hasConcept C168563851 @default.
• W2783616522 hasConcept C197934379 @default.
• W2783616522 hasConcept C203014093 @default.
• W2783616522 hasConcept C203092338 @default.
• W2783616522 hasConcept C204787440 @default.
• W2783616522 hasConcept C27081682 @default.
• W2783616522 hasConcept C2776173921 @default.
• W2783616522 hasConcept C2778329239 @default.
• W2783616522 hasConcept C2779134260 @default.
• W2783616522 hasConcept C2780501606 @default.
• W2783616522 hasConcept C2908647359 @default.
• W2783616522 hasConcept C71924100 @default.

• next